transient receptor potential cation channel, subfamily C, member 4
RGD ID:
621276
Description:
Enables calcium channel activity. Involved in calcium ion transport; positive regulation of store-operated calcium entry; and regulation of action potential firing rate. Predicted to be located in several cellular components, including basolateral plasma membrane; caveola; and cortical cytoskeleton. Predicted to be part of calcium channel complex. Predicted to be active in plasma membrane. Predicted to colocalize with cell-cell junction. Human ortholog(s) of this gene implicated in lung cancer. Orthologous to human TRPC4 (transient receptor potential cation channel subfamily C member 4); INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol; 3,3',4,4',5-pentachlorobiphenyl.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of TRPC4 mRNA
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TRPC4 protein
TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium] and TRPC4 protein affects the reaction [Carbachol results in increased transport of Calcium]
TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium] and TRPC4 protein affects the reaction [Carbachol results in increased transport of Calcium]
TRPC4 protein affects the reaction [Carbachol results in increased transport of Barium] and TRPC4 protein affects the reaction [Carbachol results in increased transport of Calcium]
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TRPC4 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TRPC4 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of TRPC4 mRNA
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of TRPC4 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA
Loss of the trpc4 gene is associated with a reduction in cocaine self-administration and reduced spontaneous ventral tegmental area dopamine neuronal activity, without deficits in learning for natural rewards.